Skip to main content

Table 1 Baseline characteristics of patients with PBT and those without PBT in different HCC stage subset in the entire cohort (n = 1255)

From: Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma

VariableBCLC 0-A (n = 804)BCLC B-C (n = 451)
PBT
n = 171)
Non-PBT
(n = 633)
P-valuePBT
(n = 176)
Non-PBT
(n = 275)
P-value
Demographic factors
 Age, yr52.9 ± 12.550.9 ± 12.10.06249.9 ± 12.249.1 ± 12.50.544
Sex, n (%)
 Male139 (81.3)557 (88.0)0.220157 (89.2)249 (90.5)0.644
 Female32 (18.7)76 (12.0) 19 (10.8)26 (9.5) 
HBsAg, n (%)
 Positive143 (83.6)545 (86.1)0.415148 (84.1)228 (82.9)0.743
 Negative28 (16.4)88 (13.9) 28 (15.9)47 (17.1) 
Cirrhosis, n (%)
 Yes123 (71.9)427 (67.5)0.265133 (75.6)198 (72)0.404
 No48 (28.1)206 (32.5) 43 (24.4)77 (28) 
Hemoglobin, g/L129.7 ± 22.8141.6 ± 17.5< 0.001131.2 ± 23.1140.3 ± 19.90.000
Platelet count, × 109 /L185.0 ± 64.5201.3 ± 92.90.008215.4 ± 113.3207.1 ± 71.30.338
Prothrombin time, s13.0 ± 1.612.7 ± 0.90.00113.1 ± 1.112.7 ± 1.30.001
ALT, U/L, median (range)39 (6565)33 (71428)0.02442.5(8237)38.0(6522)0.189
ALBI grade, n (%)
 Grade 184 (49.1)399 (63.0)< 0.00176 (43.2)160 (58.2)0.001
 Grade 284 (49.1)232 (36.7) 99 (56.3)115 (41.8) 
 Grade 33 (1.8)2 (0.3) 1 (0.5)0 
Inflammatory factors
 NLR, median (range)2.4 (0.5,13.0)1.9 (0.3,24.9)< 0.0012.5 (0.9,24.4)2.3 (0.6,18.3)0.013
 PLR, median (range)121.1 (21.61432.1)96.9 (19.4414.0)< 0.001133.9 (19.8751.0)119.6 (20.6314.6)< 0.001
 APRI, median (range)0.6 (0.1,12.2)0.5 (0.1,21.1)0.0380.6 (0.1,3.8)0.5 (0.1,5.7)0.079
Tumor characteristics
 AFP, ug/L
   ≥ 40099 (42.1)214 (33.8)0.04488 (50)149 (54.2)0.387
   < 40072 (57.9)419 (66.2) 88 (50)126 (45.8) 
  Tumor size, cm9.2 ± 6.16.2 ± 3.1< 0.00110.7 ± 3.928.9 ± 3.5< 0.001
Tumor number, n (%)
 Solitary167 (97.7)596 (94.2)0.04959 (33.5)87 (31.6)0.975
 24 (2.3)29 (4.6) 59 (33.5)102 (37.1) 
 30 (0)8 (1.2) 18 (10.2)25 (9.1) 
 40 (0)0 (0) 40 (22.8)61 (22.2) 
Tumor capsule, n (%)
 Complete137 (80.1)574 (90.7)< 0.001107 (60.8)187 (68)0.118
 Incomplete34 (19.9)59 (9.3) 69 (39.2)88 (32) 
Differentiation, n (%)
 I+ II115 (67.3)465 (73.5)0.108119 (67.6)193 (70.2)0.566
 III, IV56 (32.7)168 (26.5) 57 (32.4)82 (29.8) 
MVI, n (%)
 Yes50 (29.2)123 (19.4)0.00679 (44.9)105 (38.2)0.158
 No121 (70.8)510 (80.6) 97 (55.1)170 (61.8) 
PVTT, n (%)
 Yes00 100 (56.8)116 (42.2)0.002
 No171 (100)633 (100) 76 (43.2)159 (57.8) 
HVTT, n (%)     0.000
 Yes00 21 (11.9)7 (2.5) 
 No171 (100)633 (100) 155 (88.1)268 (97.5) 
Surgical factors
 Extent of resection, n (%)
  Major64 (37.4)194 (30.6)0.092126 (71.6)180 (65.5)0.174
  Minor107 (62.6)439 (69.4) 50 (28.4)95 (34.5) 
Type of resection, n (%)
 Anatomical62 (36.3)203 (32.1)0.30297 (55.1)150 (54.5)0.906
  Nonanatomical109 (63.7)430 (67.9) 79 (44.9)125 (45.5) 
Resection margin
  ≤ 1 cm32 (18.7)58 (9.2)< 0.00156 (31.8)122 (44.4)0.008
  > 1 cm139 (81.3)575 (90.8) 120 (68.2)153 (55.6) 
Pringle maneuver, n (%)
 Yes111 (64.9)380 (60.0)0.245114 (64.8)169 (61.4)0.477
 No60 (35.1)253 (40.0) 62 (35.2)106 (38.6) 
 Blood loss, ml, median (range)1484.7 (200,12,000)200 (50,3000)< 0.0011000 (200,10,500)300 (30,2500)< 0.001
Clavien-Dindo grade
 I4 (2.3)9 (1.4)0.0453 (1.7)8 (2.9)0.950
 II1 (0.6)9 (1.4) 2 (1.1)4 (1.5) 
 III15 (8.8)31 (4.9) 10 (5.7)18 (6.5) 
 IV2 (1.2)3 (0.5) 3 (1.7)2 (0.7) 
  1. Abbreviation: HBsAg Hepatitis B surface antigen, ABLI grade albumin to bilirubin grade, ALT anlanine transaminase, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, APRI alanine transaminase to platelet ratio index, PVTT portal vein tumor thrombus, HVTT hepatic vein tumor thrombus, MVI microscopic vascular invasion, AFP alpha fetoprotein